Clotrimazole, an imidazole antimycotic, is a potent inhibitor of angiogenesis

Japanese Journal of Cancer Research

Volumn 89, Issue 4, 1998, Pages 445-451

  Takahashi, Hiroto ^a   Abe, Mayumi ^a   Sugawara, Toshiyuki ^a   Tanaka, Katsuhiro ^a   Saito, Yasuki ^a   Fujimura, Sigefumi ^a   Shibuya, Masabumi ^b   Sato, Yasufumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Angiogenesis inhibition; Basic fibroblast growth factor; Clotrimazole; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIFUNGAL AGENT; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM ION; CHROMIUM 51; CLOTRIMAZOLE; COLLAGEN GEL; MATRIGEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0031971178     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00583.x     Document Type: Article

References (22)

1. Folkman, J. and Shing, Y. Angiogenesis. J. Biol. Chem., 267, 10931-10934 (1992).
2. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82, 4-6 (1990).
3. 2+ influx in human neutrophils is secondary to the emptying of intracellular calcium stores. Biochem. J., 277, 73-79 (1991).
4. 3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB J., 6, 2742-2747 (1992).
5. + channels by cytochrome P-450 inhibitors. J. Biol. Chem., 267, 11789-11793 (1992).
6. Benzaquen, L. R., Brugnara, C., Byers, H. R., Gattoni-Celli, S. and Halperin, J. A. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med., 1, 534-540 (1995).
7. Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M. and Shibuya, M. FLT-1 but not KDR/FLK-1 is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ., 7, 213-221 (1996).
8. Sato, Y., Shimada, T. and Takaki, R. Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro. Biochem. Biophys. Res. Commun., 180, 1098-1102 (1991).
9. Sato, Y., Abe, M. and Takaki, R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem. Biophys. Res. Commun., 172, 595-600 (1990).
10. Sato, Y., Okada, F., Abe, M., Seguchi, T., Kuwano, M., Sato, S., Furuya, A., Hanai, N. and Tamaoki, T. The mechanism for activation of latent TGF-β during co-culture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-β to smooth muscle cells. J. Cell Biol., 123, 1249-1254 (1993).
11. Abe, M., Morita, I. and Murota, S. A new in vitro method using fura-2 for the quantification of endothelial cell injury. Prostaglandins Leukot. Essent. Fatty Acids, 34, 69-74 (1988).
12. Sato, Y. and Rifkin, D. B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cells movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol., 107, 1199-1205 (1988).
13. Sato, Y., Okamura, K., Morimoto, A., Hamanaka, R., Hamaguchi, K., Shimada, T., Ono, M., Kohno, K., Sakata, T. and Kuwano, M. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp. Cell Res., 204, 223-229 (1993).
14. Passaniti, A., Taylor, R.M., Pili, R., Long, P.V., Haney, J.A., Pauly, R.R., Grant, D.S. and Martin, G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest., 67, 519-528 (1992).
15. Presta, M., Maier, J. A. M. and Ragnotti, G. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. J. Cell Biol., 109, 1877-1884 (1989).
16. Kohn, E. C., Alessandro, R., Spoonster, J., Wersto, R. P. and Liotta, L .A. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 92, 1307-1311 (1995).
17. Tamargo, R. J., Bok, R. A. and Brem, H. Angiogenesis inhibition by minocycline. Cancer Res., 51, 672-675 (1991).
18. Sato, Y., Morimoto, A., Kiue, A., Okamura, K., Hamanaka, R., Kohno, K., Kuwano, M. and Sakata, T. Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett., 322, 155-158 (1993).
19. Ono, M., Kawahara, N., Goto, D., Wakabayashi, Y., Ushiro, S., Yoshida, S., Izumi, H., Kuwano, M. and Sato, Y. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Res., 56, 1512-1516 (1996).
20. Volpert, O. V., Ward, W. F., Lingen, M. W., Chesler, L., Solt, D. B., Johnson, M. D., Molteni, A., Polverini, P. J. and Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest., 98, 671-679 (1996).
21. Klauber, N., Browne, F., Anand-Apte, B. and D'Amato, R. J. New activity of spironolactone inhibition of angiogenesis in vitro and in vivo. Circulation, 94, 2566-2571 (1996).
22. Oberste-Lehn, H., Baggesen, I. and Plempel, M. Erste klinische Erfahrungen bei System-Mykosen mit einem neuen oralen Antimykotikum. Dtsch. Med. Wochenschr., 94, 1365-1367 (1969).